Members Login
ACTG Network
  • Home
  • About
    • About the ACTG
    • Leadership and Organizational Matrix
    • ACTG Committees and Centers
    • Underrepresented Populations
    • Contact the LOC
  • Clinical Trials
    • About the Clinical Trials Process
    • Active Clinical Trials
    • Clinical Trials Resources
    • Study Result Slides
  • Sites
  • Community
    • Global Community Advisory Board
    • Community Resources
    • They Became My Family
  • Publications
  • News
    • In Memorium
    • Press Releases & Announcements
    • Newsletters
  • For Researchers
    • Submit a Proposal
    • Small Clinical Trials RFA –HIV Remission & Cure
    • Specimen Repository Website
    • HIV Databases

Houston AIDS Research Team (HART) CRS

Location

MSE R472, 6431 Fannin Street
Houston, TX 77030
United States of America

CRS Coordinator

Maria Martinez
maria.l.martinez@uth.tmc.edu
713-500-6718

CRS Leader

Roberto Arduino
roberto.c.arduino@uth.tmc.edu
713-500-6731

Studies
  • A5128: US Genomic Sampling
  • A5354: Early ART in Acute HIV
  • A5359: The LATITUDE Study
  • A5357: A Study of Long-Acting Cabotegravir Plus VRC01LS to Maintain Viral Suppression in HIV-1-Infected Adults
  • A5366: Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation with Histone Deacetylase Inhibitors
  • A5361s: Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
  • A5332: REPRIEVE Trial
  • A5322: Long-Term Follow-up of Older HIV-infected Adults in the ACTG: Addressing Issues of Aging, HIV Infection and Inflammation (HAILO)
  • A5372: Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected Individuals (RPT-DTG PK Study)
  • A5371: A Single-Arm, Open-Label, Pilot Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome with Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)
  • A5379: B-Enhancement of HBV vaccination in persons living with HIV (BEe-HIVe): Evaluation of HEPLISAV-B
  • A5391: Doravirine for Persons with Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide (The Do IT Study)

Mission

The mission of the ACTG Network
is to cure HIV and reduce the
burden of disease due to HIV
and its complications, including
tuberculosis and viral hepatitis.

Useful Links

Government Resources
Clinical Trials Resources
Grants and Contracts
New Members

© ACTG. All Rights Reserved. | admin login